{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:03:25Z","timestamp":1791655405552,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40123-026-01413-1","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:53:18Z","timestamp":1780498398000},"page":"2475-2485","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Spectrally Resolved (Colour-Coded) Fundus Autofluorescence Using the EIDON System in Vitreoretinal Lymphoma"],"prefix":"10.1007","volume":"15","author":[{"given":"Alessandro","family":"Marchese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Sacconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Menean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bordato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Battista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Modorati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3292-9581","authenticated-orcid":false,"given":"Giuseppe","family":"Querques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Miserocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"issue":"11","key":"1413_CR1","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1634\/theoncologist.2011-0210","volume":"16","author":"CC Chan","year":"2011","unstructured":"Chan CC, Rubenstein JL, Coupland SE, et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist. 2011;16(11):1589\u201399. https:\/\/doi.org\/10.1634\/theoncologist.2011-0210.","journal-title":"Oncologist"},{"issue":"1","key":"1413_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-018-0120-4","volume":"4","author":"JS Pulido","year":"2018","unstructured":"Pulido JS, Johnston PB, Nowakowski GS, et al. The diagnosis and treatment of primary vitreoretinal lymphoma: a review. Int J Retina Vitreous. 2018;4(1):18. https:\/\/doi.org\/10.1186\/s40942-018-0120-4.","journal-title":"Int J Retina Vitreous"},{"issue":"1","key":"1413_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41433-021-01887-2","volume":"37","author":"LA Dalvin","year":"2023","unstructured":"Dalvin LA, Pulido JS, Shields CL, et al. Vitreoretinal lymphoma: central nervous system lymphoma risk with unilateral or bilateral ocular tumour. A multicentre collaboration. Eye (Lond). 2023;37(1):54\u201361. https:\/\/doi.org\/10.1038\/s41433-021-01887-2.","journal-title":"Eye (Lond)"},{"key":"1413_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/ICU.0000000000000620","volume":"30","author":"JS Takhar","year":"2019","unstructured":"Takhar JS, Doan TA, Gonzales JA. Primary vitreoretinal lymphoma: empowering our clinical suspicion. Curr Opin Ophthalmol. 2019;30:491\u20139. https:\/\/doi.org\/10.1097\/ICU.0000000000000620.","journal-title":"Curr Opin Ophthalmol"},{"key":"1413_CR5","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1097\/IAE.0000000000002319","volume":"39","author":"E Miserocchi","year":"2019","unstructured":"Miserocchi E, Ferreri AJM, Giuffre C, et al. Myd88 L265p mutation detection in the aqueous humor of patients with vitreoretinal lymphoma. Retina. 2019;39:679\u201384. https:\/\/doi.org\/10.1097\/IAE.0000000000002319.","journal-title":"Retina"},{"issue":"2","key":"1413_CR6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/IAE.0b013e31829977fa","volume":"34","author":"M Casady","year":"2014","unstructured":"Casady M, Faia L, Nazemzadeh M, et al. Fundus autofluorescence patterns in primary intraocular lymphoma. Retina. 2014;34(2):366\u201372. https:\/\/doi.org\/10.1097\/IAE.0b013e31829977fa.","journal-title":"Retina"},{"key":"1413_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1616769","author":"MV Cicinelli","year":"2019","unstructured":"Cicinelli MV, Marchese A, Miserocchi E, et al. Retinal and choroidal changes of vitreoretinal lymphoma from active to remission phase after intravitreal rituximab. Ocul Immunol Inflamm. 2019. https:\/\/doi.org\/10.1080\/09273948.2019.1616769.","journal-title":"Ocul Immunol Inflamm"},{"key":"1413_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1648835","author":"A Marchese","year":"2019","unstructured":"Marchese A, Agarwal A, Miserocchi E, et al. Features of retinitis-like lesions in vitreoretinal lymphoma. Ocul Immunol Inflamm. 2019. https:\/\/doi.org\/10.1080\/09273948.2019.1648835.","journal-title":"Ocul Immunol Inflamm"},{"key":"1413_CR9","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1136\/bjophthalmol-2018-313491","volume":"103","author":"A Marchese","year":"2019","unstructured":"Marchese A, Miserocchi E, Giuffre C, et al. Aurora borealis and string of pearls in vitreoretinal lymphoma: patterns of vitreous haze. Br J Ophthalmol. 2019;103:1656\u20139. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-313491.","journal-title":"Br J Ophthalmol"},{"key":"1413_CR10","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1136\/bjophthalmol-2017-311612","volume":"102","author":"RJ Barry","year":"2018","unstructured":"Barry RJ, Tasiopoulou A, Murray PI, et al. Characteristic optical coherence tomography findings in patients with primary vitreoretinal lymphoma: a novel aid to early diagnosis. Br J Ophthalmol. 2018;102:1362\u20136. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311612.","journal-title":"Br J Ophthalmol"},{"key":"1413_CR11","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1159\/000447412","volume":"236","author":"C Mapelli","year":"2016","unstructured":"Mapelli C, Invernizzi A, Barteselli G, et al. Multimodal imaging of vitreoretinal lymphoma. Ophthalmologica. 2016;236:166\u201374. https:\/\/doi.org\/10.1159\/000447412.","journal-title":"Ophthalmologica"},{"key":"1413_CR12","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.ajo.2008.12.025","volume":"147","author":"C Fardeau","year":"2009","unstructured":"Fardeau C, Lee CP, Merle-Beral H, et al. Retinal fluorescein, indocyanine green angiography, and optic coherence tomography in non-Hodgkin primary intraocular lymphoma. Am J Ophthalmol. 2009;147:886\u201394. https:\/\/doi.org\/10.1016\/j.ajo.2008.12.025.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"1413_CR13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jamaophthalmol.2018.5835","volume":"137","author":"GG Deak","year":"2019","unstructured":"Deak GG, Goldstein DA, Zhou M, et al. Vertical hyperreflective lesions on optical coherence tomography in vitreoretinal lymphoma. JAMA Ophthalmol. 2019;137(2):194\u20138. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.5835.","journal-title":"JAMA Ophthalmol"},{"key":"1413_CR14","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.ajo.2014.08.031","volume":"158","author":"CE Pang","year":"2014","unstructured":"Pang CE, Shields CL, Jumper JM, et al. Paraneoplastic cloudy vitelliform submaculopathy in primary vitreoretinal lymphoma. Am J Ophthalmol. 2014;158:1253\u201361. https:\/\/doi.org\/10.1016\/j.ajo.2014.08.031.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1413_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/IAE.0b013e3181b408a2","volume":"30","author":"T Ishida","year":"2010","unstructured":"Ishida T, Ohno-Matsui K, Kaneko Y, et al. Fundus autofluorescence patterns in eyes with primary intraocular lymphoma. Retina. 2010;30(1):23\u201332. https:\/\/doi.org\/10.1097\/IAE.0b013e3181b408a2.","journal-title":"Retina"},{"key":"1413_CR16","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1136\/bjophthalmol-2017-310881","volume":"102","author":"E Borrelli","year":"2018","unstructured":"Borrelli E, Lei J, Balasubramanian S, et al. Green emission fluorophores in eyes with atrophic age-related macular degeneration: a colour fundus autofluorescence pilot study. Br J Ophthalmol. 2018;102:827\u201332. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310881.","journal-title":"Br J Ophthalmol"},{"key":"1413_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-311849","author":"E Borrelli","year":"2018","unstructured":"Borrelli E, Nittala MG, Abdelfattah NS, et al. Comparison of short-wavelength blue-light autofluorescence and conventional blue-light autofluorescence in geographic atrophy. Br J Ophthalmol. 2018. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-311849.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1413_CR18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1167\/iovs.18-25755","volume":"60","author":"C Dysli","year":"2019","unstructured":"Dysli C, Muller PL, Birtel J, et al. Spectrally resolved fundus autofluorescence in ABCA4-related retinopathy. Invest Ophthalmol Vis Sci. 2019;60(1):274\u201381. https:\/\/doi.org\/10.1167\/iovs.18-25755.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1413_CR19","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1080\/09273948.2020.1787460","volume":"29","author":"C Giuffre","year":"2021","unstructured":"Giuffre C, Cicinelli MV, Marchese A, et al. Clinical experience in a large cohort of patients with vitreoretinal lymphoma in a single center. Ocul Immunol Inflamm. 2021;29:472\u20138. https:\/\/doi.org\/10.1080\/09273948.2020.1787460.","journal-title":"Ocul Immunol Inflamm"},{"issue":"7","key":"1413_CR20","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1167\/iovs.06-0031","volume":"48","author":"N Cassoux","year":"2007","unstructured":"Cassoux N, Giron A, Bodaghi B, et al. IL-10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma. Invest Ophthalmol Vis Sci. 2007;48(7):3253\u20139. https:\/\/doi.org\/10.1167\/iovs.06-0031.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1413_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ajo.2021.11.023","volume":"238","author":"F Pichi","year":"2022","unstructured":"Pichi F, Dolz-Marco R, Francis JH, et al. Advanced OCT analysis of biopsy-proven vitreoretinal lymphoma. Am J Ophthalmol. 2022;238:16\u201326. https:\/\/doi.org\/10.1016\/j.ajo.2021.11.023.","journal-title":"Am J Ophthalmol"},{"key":"1413_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/2515841420917781","volume":"12","author":"A Marchese","year":"2020","unstructured":"Marchese A, Agarwal A, Moretti AG, et al. Advances in imaging of uveitis. Ther Adv Ophthalmol. 2020;12:2515841420917781. https:\/\/doi.org\/10.1177\/2515841420917781.","journal-title":"Ther Adv Ophthalmol"},{"key":"1413_CR23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/IAE.0000000000003352","volume":"42","author":"A Marchese","year":"2022","unstructured":"Marchese A, Cicinelli MV, Cavalleri M, et al. Chorioretinal atrophy in vitreoretinal lymphoma: risk factors and visual outcomes. Retina. 2022;42:561\u20138. https:\/\/doi.org\/10.1097\/IAE.0000000000003352.","journal-title":"Retina"},{"issue":"1","key":"1413_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000519300","volume":"8","author":"A Marchese","year":"2022","unstructured":"Marchese A, Cicinelli MV, Bandello F, et al. Hemorrhagic mass-like presentation of vitreoretinal lymphoma. Ocul Oncol Pathol. 2022;8(1):9\u201315. https:\/\/doi.org\/10.1159\/000519300.","journal-title":"Ocul Oncol Pathol"},{"key":"1413_CR25","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3109\/09273948.2016.1139731","volume":"25","author":"S Mahajan","year":"2017","unstructured":"Mahajan S, Nijhawan R, Rajwanshi A, et al. Clinical characteristics of primary vitreoretinal lymphoma in an Indian population. Ocul Immunol Inflamm. 2017;25:633\u20138. https:\/\/doi.org\/10.3109\/09273948.2016.1139731.","journal-title":"Ocul Immunol Inflamm"},{"key":"1413_CR26","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/s0161-6420(93)31469-7","volume":"100","author":"SM Whitcup","year":"1993","unstructured":"Whitcup SM, de Smet MD, Rubin BI, et al. Intraocular lymphoma Clinical and histopathologic diagnosis. Ophthalmology. 1993;100:1399\u2013406. https:\/\/doi.org\/10.1016\/s0161-6420(93)31469-7.","journal-title":"Ophthalmology"},{"key":"1413_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0000000000000952","author":"MV Cicinelli","year":"2019","unstructured":"Cicinelli MV, Marchese A, Miserocchi E, et al. Multiple retinal pigment epithelium apertures associated with pseudo-vitelliform lymphomatous maculopathy. Retin Cases Brief Rep. 2019. https:\/\/doi.org\/10.1097\/ICB.0000000000000952.","journal-title":"Retin Cases Brief Rep"},{"key":"1413_CR28","doi-asserted-by":"publisher","first-page":"4911","DOI":"10.1158\/0008-5472.CAN-08-2761","volume":"69","author":"SM Pantanelli","year":"2009","unstructured":"Pantanelli SM, Li Z, Fariss R, et al. Differentiation of malignant B-lymphoma cells from normal and activated T-cell populations by their intrinsic autofluorescence. Cancer Res. 2009;69:4911\u20137. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-2761.","journal-title":"Cancer Res"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01413-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01413-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01413-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:23:10Z","timestamp":1782739390000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01413-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1413"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01413-1","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alessandro Marchese has nothing to disclose. Matteo Menean has nothing to disclose. Alessandro Bordato has nothing to disclose. Marco Battista has nothing to disclose. Giulio Modorati has nothing to disclose. Elisabetta Miserocchi has nothing to disclose. Riccardo Sacconi serves as a consultant for Allergan, Bayer, Novartis, and Zeiss. Francesco Bandello serves as a consultant for Allergan, Bayer, Boehringer-Ingelheim, Fidia Sooft, Hofmann La Roche, Novartis, NTC Pharma, SIFI, Thrombogenics, and Zeiss. Giuseppe Querques serves as a consultant for Alimera Sciences, Allergan Inc., Amgen, Heidelberg, KBH, LEH Pharma, Lumithera, Novartis, Bayer Schering-Pharma, Sandoz, SIFI, Sooft-Fidia, and Zeiss. Giuseppe Querques is an Editorial Board member of Ophthalmology and Therapy. Giuseppe Querques was not involved in the selection of peer reviewers for the manuscript or in any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This retrospective study involves human participants and was performed in accordance with the Helsinki Declaration of 1964, and its later amendments. All subjects provided informed consent to participate in the study and publication of the information. The ethics committee of IRCCS Ospedale San Raffaele was notified about this study. According to Italian law, retrospective studies require the ethics committee to be notified, but do not require its approval. Written informed consent was waived due to the retrospective design of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}